Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mocroft

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Lancet (London, England)|April 28, 1999
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study GroupG J Weverling, A Mocroft, B Ledergerber, et al.
Antiviral Therapy|May 15, 2002
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA studyA Mocroft, A N Phillips, N Friis-Møller, et al.
AIDS (London, England)|September 14, 2000
Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV MedicineM Youle, G Janossy, W Turnbull, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 24, 1999
Changes in AIDS-defining illnesses in a London Clinic, 1987-1998A Mocroft, C A Sabin, M Youle, et al.
The New England Journal of Medicine|February 24, 2001
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study GroupsB Ledergerber, A Mocroft, P Reiss, et al.
Open Forum Infectious Diseases|June 8, 2018
Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell TransplantationI P Lodding, C da Cunha Bang, S S Sørensen, et al.
Lancet (London, England)|December 16, 1998
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study GroupA Mocroft, S Vella, T L Benfield, et al.
HIV Medicine|February 26, 2015
Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialA C Achhra, A Mocroft, M J Ross, et al.
HIV Medicine|July 23, 2013
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDAD Grint, L Peters, C Schwarze-Zander, et al.
AIDS (London, England)|February 24, 2001
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centreA Mocroft, M Youle, A Moore, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Lancet (London, England)|April 28, 1999
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study GroupG J Weverling, A Mocroft, B Ledergerber, et al.
Antiviral Therapy|May 15, 2002
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA studyA Mocroft, A N Phillips, N Friis-Møller, et al.
AIDS (London, England)|September 14, 2000
Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV MedicineM Youle, G Janossy, W Turnbull, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 24, 1999
Changes in AIDS-defining illnesses in a London Clinic, 1987-1998A Mocroft, C A Sabin, M Youle, et al.
The New England Journal of Medicine|February 24, 2001
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study GroupsB Ledergerber, A Mocroft, P Reiss, et al.
Open Forum Infectious Diseases|June 8, 2018
Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell TransplantationI P Lodding, C da Cunha Bang, S S Sørensen, et al.
Lancet (London, England)|December 16, 1998
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study GroupA Mocroft, S Vella, T L Benfield, et al.
HIV Medicine|February 26, 2015
Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialA C Achhra, A Mocroft, M J Ross, et al.
HIV Medicine|July 23, 2013
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDAD Grint, L Peters, C Schwarze-Zander, et al.
AIDS (London, England)|February 24, 2001
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centreA Mocroft, M Youle, A Moore, et al.
Pageof 12